country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-153617

Copy Link Print Information

FOXO1-IN-3

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.47%
CAS. Nr.: 2451093-95-9
Formel: C₂₂H₂₃N₇O
Molecular Weight:401.46

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

FOXO1-IN-3 Chemical Structure

CAS. Nr.: 2451093-95-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

FOXO1^[1]

Alle FOXO Isoform-spezifische Produkte anzeigen :

FOXO1
FOXO3

In Vitro

FOXO1-IN-3 (Compound 10) (10 μM, 6 h) suppresses cAMP/Dexamethasone (HY-14648) induced G6pc and Pck1 mRNA expression in primary hepatocytes isolated from normal mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

primary hepatocytes isolated from normal mice
Concentration:

10 μM
Incubation Time:

6 h
Result:

Inhibited cAMP/Dexamethasone (HY-14648) induced G6pc and Pck1 mRNA expression, and did not affect Foxo1 levels.

In Vivo

FOXO1-IN-3 (Compound 10) (16 mg/kg, p.o., twice daily, for 10 days) reduces blood glucose in db/db mice^[1].
FOXO1-IN-3 (16 mg/kg, p.o., twice daily, for 7 days) and FGF21 (0.45 mg/kg) has synergistic glucose-lowering effects in Streptozotocin (HY-13753) induced β-cell-ablated diabetic mice^[1].
FOXO1-IN-3 (1 mg/kg for i.v., 10 mg/kg for p.o.) shows significant plasma exposure and oral bioavailability despite relatively short half-life in mice^[1].
PK properties of FOXO1-IN-3 (compound 10)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

db/db mice^[2]
Dosage:

16 mg/kg
Administration:

p.o., twice daily, for 10 days
Result:

Reduced blood glucose, increased HOMA-β (an indicator of β-cell function).
Did not significantly affect insulin levels.
Had no apparent effect on hepatic histology.

Chemical Information

CAS. Nr. 2451093-95-9
Appearance Solid
Molecular Weight 401.46
Formel C₂₂H₂₃N₇O
Color White to light yellow
SMILES

O=C(C1=CC=C(N2CCN(CC2)C)C=C1)NC3=CC(C4=NC5=C(N4)C=CC=C5)=NN3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Dose (mg/kg)	parameters	value
i.v. (1 mg/kg)	T_1/2	1.23 h
	AUCinf	1.86 μM·h
	CL	22.7 mL/kg·min
p.o. (10 mg/kg)	T_max	0.67 h
	AUCinf	4.66 μM·h
	F%	25.5%

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

CNS Neurosci Ther

A Decoy Oligodeoxynucleotides Disturbing Forkhead Box O3 Mediated ctnna2 Transcriptional Repression Prevents Postoperative Neurocognitive Disorder in Mice. [Abstract]

2025 Aug;31(8):e70454. PMID: 40859434

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (249.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4909 mL

12.4545 mL

24.9091 mL

5 mM

0.4982 mL

2.4909 mL

4.9818 mL

10 mM

0.2491 mL

1.2455 mL

2.4909 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (6.23 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee YK, et al. FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice. Mol Metab. 2021 Jul;49:101187. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4909 mL	12.4545 mL	24.9091 mL	62.2727 mL
	5 mM	0.4982 mL	2.4909 mL	4.9818 mL	12.4545 mL
	10 mM	0.2491 mL	1.2455 mL	2.4909 mL	6.2273 mL
	15 mM	0.1661 mL	0.8303 mL	1.6606 mL	4.1515 mL
	20 mM	0.1245 mL	0.6227 mL	1.2455 mL	3.1136 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4909 mL
	30 mM	0.0830 mL	0.4152 mL	0.8303 mL	2.0758 mL
	40 mM	0.0623 mL	0.3114 mL	0.6227 mL	1.5568 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0379 mL
	80 mM	0.0311 mL	0.1557 mL	0.3114 mL	0.7784 mL
	100 mM	0.0249 mL	0.1245 mL	0.2491 mL	0.6227 mL

Keywords

FOXO1-IN-3

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

FOXO1-IN-3

Metabolism/Protease Compound Library

Anti-diabetic Compound Library

Orally Active Compound Library

Transcription Factor-Targeted Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FOXO1-IN-3

Alle FOXO Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

FOXO1-IN-3

Metabolism/Protease Compound Library

Anti-diabetic Compound Library

Orally Active Compound Library

Transcription Factor-Targeted Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FOXO1-IN-3

Alle FOXO Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

FOXO1-IN-3 Related Classifications

HY-153617 Related Classifications